Scarica l'app Stockscreener
0.305
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CARA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.305
Aprire:
$0.3019
Volume 24 ore:
155.31K
Relative Volume:
0.33
Capitalizzazione di mercato:
$16.73M
Reddito:
$20.97M
Utile/perdita netta:
$-118.51M
Rapporto P/E:
-0.1481
EPS:
-2.06
Flusso di cassa netto:
$-94.45M
1 W Prestazione:
-6.90%
1M Prestazione:
+14.83%
6M Prestazione:
-59.54%
1 anno Prestazione:
-69.80%
Intervallo 1D:
$0.30
$0.315
Intervallo di 1 settimana:
$0.278
$0.33
Portata 52W:
$0.24
$1.31
Cara Therapeutics Inc Stock (CARA) Company Profile
Nome
Cara Therapeutics Inc
Settore
Industria
Telefono
203-406-3700
Indirizzo
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Confronta CARA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CARA | 0.3052 | 16.73M | 20.97M | -118.51M | -94.45M | -2.06 |
| VRTX | 449.62 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.76 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 598.25 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.36 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.28 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-06-30 | Downgrade | Janney | Buy → Neutral |
| 2017-06-30 | Reiterato | Laidlaw | Buy |
| 2017-06-30 | Reiterato | Stifel | Buy |
| 2017-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-28 | Reiterato | Laidlaw | Buy |
| 2017-03-10 | Reiterato | Laidlaw | Buy |
| 2016-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-08 | Reiterato | Needham | Buy |
Mostra tutto
Cara Therapeutics Inc Borsa (CARA) Ultime notizie
Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Stamford’s Cara Therapeutics continues financial struggles; 10-employee workforce down 91% - Hartford Business Journal
Cara Therapeutics Inc. (CARA) Quarterly 10-Q Report - Quartzy
Cara: Q3 Earnings Snapshot - Houston Chronicle
Cara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Rigel to Present at the Jefferies London Healthcare Conference - Quantisnow
CARGO Therapeutics, Inc. (NASDAQ:CRGX) Receives Average Rating of “Buy” from Analysts - Defense World
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Analysts - Defense World
Cara Therapeutics CEO Posner sells shares worth $1,063 - Investing.com India
Cara Therapeutics CEO Posner sells shares worth $1,063 By Investing.com - Investing.com Australia
Cara Operations (TSE:CARA) Stock Price Down 2.4% – Here’s Why - Defense World
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues - Simply Wall St
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update - Quantisnow
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
CSL Limited Reports 13.5% Stake In Cara Therapeutics - XM
Truist Financial Initiates Coverage on Amentum (NYSE:AMTM) - Defense World
América Móvil (NYSE:AMX) PT Lowered to $20.80 - Defense World
Riskified Ltd. (NYSE:RSKD) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Heritage Global Inc. (NASDAQ:HGBL) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Dimensional Fund Advisors LP Purchases 55,636 Shares of VirTra, Inc. (NASDAQ:VTSI) - Defense World
Renaissance Technologies LLC Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Financial Health Report: Cara Therapeutics Inc (CARA)’s Ratios Tell a Tale - The Dwinnex
What technical indicators reveal about CARA stock - US Post News
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Quantisnow
Medical Marijuana Market Report 2024Growth, Forecast In The Latest Research - WhaTech
Cannabinoid Derived Pharmaceutical Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World
Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex
Cara Therapeutics, Inc. (NASDAQ:CARA) Sees Large Increase in Short Interest - Defense World
Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World
G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
WesBanco, Inc. (NASDAQ:WSBC) Receives Consensus Rating of “Hold” from Analysts - Defense World
Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com
Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Carmat launches capital increase, stock plummets - Marketscreener.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
Most Promising New Drugs for Hidradenitis Suppurativa, with Raj Chovatiya, MD, PhD - MD Magazine
The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News
Cara Therapeutics Inc (CARA)’s Day in Review: Closing at 0.26, Down by -2.85 - The Dwinnex
CARA’s Stock Market Adventure: -62.18% YTD Growth Amidst Volatility - The InvestChronicle
How to interpret Cara Therapeutics Inc (CARA)’s stock chart patterns - US Post News
Pruritus Therapeutics Market Competition & Segment Analysis – Actavis Plc, Amgen Inc., Bristol-Myers Squibb, Cara Therapeutics, Cipla – Cauverynews - Cauverynews
Metric Deep Dive: Understanding Cara Therapeutics Inc (CARA) Through its Ratios - The Dwinnex
Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging - openPR
Does Cara Therapeutics Inc (CARA) offer a good opportunity for investors? - SETE News
Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World
Cara Therapeutics Inc Azioni (CARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cara Therapeutics Inc Azioni (CARA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Posner Christopher | PRESIDENT AND CEO |
Aug 01 '24 |
Sale |
0.35 |
4,149 |
1,452 |
172,436 |
| Posner Christopher | PRESIDENT AND CEO |
May 02 '24 |
Sale |
0.75 |
3,936 |
2,952 |
176,585 |
| Goncalves Joana | CHIEF MEDICAL OFFICER |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
53,365 |
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
88,247 |
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 29 '24 |
Sale |
0.89 |
3,293 |
2,931 |
91,000 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 29 '24 |
Sale |
0.89 |
5,834 |
5,192 |
180,521 |
| Goncalves Joana | CHIEF MEDICAL OFFICER |
Feb 29 '24 |
Sale |
0.89 |
3,293 |
2,931 |
56,118 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 08 '24 |
Sale |
0.53 |
35,575 |
18,855 |
186,355 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 01 '24 |
Sale |
0.55 |
4,981 |
2,740 |
221,930 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):